Please try another search
EOM Pharmaceutical Holdings, Inc., formerly ImmunoCellular Therapeutics, Ltd. is a clinical-stage pharmaceutical company. The Company is focused on the development of novel therapeutics and delivery technologies for the treatment of inflammatory conditions and ocular diseases. The Company’s portfolio consists of two product candidates: EOM613 and EOM147. EOM613 is an investigational, dynamically dual-acting immunomodulator. EOM613 is a peptide-nucleic acid solution and, based on past clinical data, have both an anti-inflammatory and pro-inflammatory effect at the site of cytokine and chemokine overactivity, and a pro-inflammatory effect when needed. EOM 147 is an investigational, broad-spectrum aminosterol with an intracellular mechanism for the treatment of retinal diseases. EOM is designed to counteract with the severe inflammatory effects of viruses, such as a cytokine storm or hyperimmune response following infection with the novel coronavirus that cause COVID-19.
Name | Age | Since | Title |
---|---|---|---|
Cohava Gelber | 64 | 2009 | Member of Scientific Advisory Board |
Julie Kampf | 60 | 2022 | Independent Director |
Irach B. Taraporewala | 66 | 2021 | CEO, President & Director |
Eli Goldberger | 32 | 2021 | Founder, Chairman & COO |
Frank L. Douglas | 78 | 2022 | Independent Director |
Robert Lehman | 61 | 2022 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review